Society for Translational Oncology


Highlights from STO's educational activities, including content associated with the Society and its journal The Oncologist. RSS Feed URL

Society for Translational Oncology navigateright Episode

Beyond PARP1: Ribosylation as a Target for Cancer Therapy

Victoria Richon, PhD 
Ribon Therapeutics 

Video Overview:

Lecture Slides

Much of the attention on the PARP family has been focused on the polyPARP PARP1, and inhibitors targeting PARP1 have been approved for the treatment of cancer. Recently, data are emerging regarding the role of the monoPARPs distinct from PARP1. The specific substrates and functions of the twelve monoPARP proteins are currently being elucidated, and these recent discoveries indicate that several monoPARPs, including PARP7, play important roles in cancer survival pathways.

These lectures are designed to meet the educational needs of physicians and scientists in academic and practice settings who wish to advance their knowledge of the research into new treatments and improve their competence in the care of patients with cancer.